Bioxyne Limited (ASX:BXN) is an international Australian life sciences company headquartered in Sydney, and parent company of the Breathe Life Sciences Group. Bioxyne and wholly owned subsidiary Breathe Life Sciences manufacture and distribute novel medicines (cannabis, MDMA, Psilocybin) and consumer health products (CBD, functional mushrooms, other) in Australia, Europe, UK, Japan, and USA.

In Australia, Breathe Life Sciences holds a TGA manufacturing license, controlled substance licenses to import, export, and wholesale Schedule 3,4, 8 and 9 products, operating primarily business to business. Outside of Australia, the business has manufacturing and distribution centres in Japan, the UK, and Europe, and operates direct to consumer supply of its trademarked Dr Watson® brand.

For more information on Bioxyne, please visit https://bioxyne.com